SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing significant volatility and a steep sell-off after disclosing that Marvell canceled its purchase orders due to a confidentiality breach caused by public remarks from management. The community is sharply divided, with many retail investors expressing frustration over the lack of transparency while others view the dip as an opportunity to accumulate shares, betting on the long-term viability of the company's photonics technology.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is seeing heightened volatility as the community debates its long-term AI strategy, driven by reports that OpenAI may partner with the company to develop custom smartphone processors. Investors remain divided, with some betting on a reversal and AI-driven growth, while others express frustration over recent price fluctuations and persistent short-term bearish sentiment.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following a positive readout for its late-stage HAE study, which bolstered the bull case for its in vivo CRISPR platform despite intense scrutiny from shorts. Investors are heavily focused on the implications for future drug adoption, institutional positioning, and the potential for a significant short squeeze as the company moves toward regulatory milestones.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corp is experiencing significant volatility and heavy trading volume as investors debate whether a long-standing insider selling overhang from AE Industrial Partners has finally cleared. The community remains deeply divided, with bulls pointing to strong contract wins and potential tailwinds from the broader space economy, while bears remain skeptical about consistent execution and continued selling pressure.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is seeing significant retail attention driven by high volatility and heavy short interest, leading traders to discuss the potential for a short squeeze despite skepticism surrounding the company's fundamentals and recent price action. The community remains divided, with some actively trading the sharp price swings while others warn of the risks associated with the stock's unpredictable performance.

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

Sagimet Biosciences Inc

Sagimet Biosciences is trending as investors weigh the significant valuation disconnect between its recent acne trial success and its current market capitalization, while speculation intensifies regarding potential acquisition interest from larger players in the MASH space. Community sentiment remains split between long-term confidence in the drug's multi-indication pipeline and short-term frustration over price volatility and the lack of immediate monotherapy funding for its MASH program.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is under investor pressure following earnings results that highlighted the looming TDAPA reimbursement transition, causing shareholders to scrutinize management's conservative 2026 outlook and the lack of clarity regarding long-term commercial growth. While the company authorized a significant share buyback and maintains a profitable profile, the community remains divided, with debates intensifying over the effectiveness of current leadership and the strategic importance of upcoming REZZAYO trial data.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as investors react to a major leadership overhaul, including the departure of former CEO Peter Greenleaf and the appointment of Chairman Kevin Tang to lead the company. The community is buzzing with optimism that this management pivot, paired with Tang's aggressive cost-cutting measures, signals a strategic shift aimed at accelerating a potential buyout.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is experiencing heightened volatility following an unverified report alleging the cancellation of a major contract, which the community is debating as a potential market manipulation attempt or "hit job" by short sellers. Traders are closely monitoring the stock ahead of upcoming earnings, while discussions remain polarized between those dismissing the negative news as FUD and those concerned about the company's long-term leadership and transparency.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing heightened volatility as the community debates a potential double-top formation near $79,000 against optimistic sentiment surrounding institutional ETF inflows and corporate treasury accumulation. Market participants are intensely focused on key technical resistance levels and upcoming macroeconomic catalysts, with social discourse split between bullish expectations for a breakout and bearish warnings of a deeper liquidity flush.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP

Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class...

Wall Street Zen Upgrades Prima BioMed (NASDAQ:IMMP) to Hold

Wall Street Zen upgraded Prima BioMed to a "hold" rating in a report on Saturday...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep...

Prima BioMed Sees Unusually Large Options Volume (NASDAQ:IMMP)

Prima BioMed Ltd (NASDAQ:IMMP - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 8,815 call options on the company. This represents an increase...

From Sneakers to AI Powerhouse

Today’s tape includes microcap breakouts, biotech catalysts, and radical corporate reinventions colliding in a market that’s increasingly rewarding narrative velocity over legacy stability. $IMMP, $TGNT, $AGAE, $BIRD, $VSA, $CIIT, $LRHC, $NNBR, $SNAP

IMMP Investor Alert: Immutep Ltd. Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial Viability : Levi & Korsinsky

IMMP Investor Alert: Immutep Ltd. Securities Fraud Investigation - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Material Risks Related To Trial...

<ul class="summary-bullets"><li>The FDA issues ODD to therapies showing encouraging results for treating diseases affecting fewer than 200,000 people.</li><li>This comes after a successful trial of the company’s Eftilagimod Alfa, tested with radiotherapy and the immunotherapy drug Keytruda in patients before surgery.</li><li>Last month, a trial for Efti in first-line non-small cell lung cancer was stopped, leading to an 82% intraday plunge in IMMP stock.</li></ul>Shares of Immutep Ltd (IMMP) surged around 150% in pre-market trading on Wednesday, on track for their biggest intraday gains since Dec. 10, 2020, after the biotech firm announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for its drug to treat soft tissue sarcoma.The decision is supported by encouraging results from the Phase II EFTISARC-NEO trial, in which Eftilagimod Alfa (Efti) was tested with radiotherapy and the immunotherapy drug Keytruda in patients before surgery. In 38 patients, the study met its primary endpoint, showing a median tumor hyalinization/fibrosis of 51.5%, well above the 35% target. This essentially means that half of the tumor tissue showed signs of being replaced by scar-like tissue.The FDA issues ODD to therapies showing encouraging results for treating diseases affecting fewer than 200,000 people. The designation comes with additional benefits, including regulatory assistance, tax credits, fee waivers, and 7 years of market exclusivity upon approval.<h2 class="st-heading-2">Silver Lining After Phase III TACTI-004 Trial Was Abandoned</h2>In March, Immutep announced that its Phase III TACTI-004 trial of Efti in first-line non-small cell lung cancer will be stopped following an interim review by the Independent Data Monitoring Committee (IDMC), which found that the study was unlikely to meet its goals. Following this decision, Immutep expects its cash runway to extend beyond its earlier guidance of the second quarter (Q2) of 2027.The stock plunged 82% after the March 13 update, dropping below $1 and failing to recover since then. Prior to the update, IMMP shares were placed under a trading halt for five sessions.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on <a href="https://stocktwits.com/symbol/IMMP">IMMP stock</a> flipped to ‘extremely bullish’ from ‘bearish’ a day earlier.One user expects the latest news to lead to new partnerships or even an acquisition.&nbsp;<stembedurl>https://stocktwits.com/joe77w/message/650314490</stembedurl>However, another user said that the Phase III TACTI-004 failure “still defines the long-term trend.”<stembedurl>https://stocktwits.com/Treasuremovers/message/650314616</stembedurl>The stock has crashed around 80% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Last week, Baird maintained AYI’s ‘neutral’ rating but cut price target to $320 from $375. (Representative image: Getty Images)

Why Did IMMP Stock Surge 150% In Pre-Market Today?

Immutep announced that the U.S. FDA granted Orphan Drug Designation for its drug for the treatment of soft-tissue sarcoma.

Why Is This Beaten-Down Biotech Surging 150% In Pre-Market Today?

Equity

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP PR Newswire NEW YORK, April 2, 2026 NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP...

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

IMMP
Immutep LTD ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMMP News

IMMPImmutep LTD ADR